People · Operator

Jim D. Young

Named in public records as an officer, director or promoter · active 2016–2019 · Other Health Care

1
Companies
2
Filings
$51.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Impel Neuropharma IncOther Health CareSeries B$51.1M$34.5M2016
Operator network

Jim D. Young at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Mahendra D. Shah · 2 companies · 1 sharedMahendra D. ShahRobert D. Mittendorff · 2 companies · 1 sharedRobert D. Mittend…Aaron D. Royston · 1 companies · 1 sharedAaron D. RoystonAdrian D. Adams · 1 companies · 1 sharedAdrian D. AdamsAli D. Satvat · 1 companies · 1 sharedAli D. SatvatDavid D. Allison · 1 companies · 1 sharedDavid D. AllisonDiane D. Wilfong · 1 companies · 1 sharedDiane D. WilfongJohn D. Hoekman · 1 companies · 1 sharedJohn D. HoekmanJohn D. Leaman · 1 companies · 1 sharedJohn D. LeamanJon D. Congleton · 1 companies · 1 sharedJon D. CongletonMichael P. Hite · 1 companies · 1 sharedMichael P. HiteRodney D. Ho · 1 companies · 1 sharedRodney D. HoStewart D. Parker · 1 companies · 1 sharedStewart D. ParkerTim D. Nelson · 1 companies · 1 sharedTim D. NelsonImpel Neuropharma Inc · $51.1M raisedImpel Neuropharma IncJim D. YoungJY
Jim D. Young Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jim D. Young on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert D. Mittendorff12
Mahendra D. Shah12
Rodney D. Ho11
Michael P. Hite11
John D. Leaman11
Aaron D. Royston11
Ali D. Satvat11
Adrian D. Adams11
David D. Allison11
Diane D. Wilfong11
Tim D. Nelson11
Stewart D. Parker11
Jon D. Congleton11
John D. Hoekman11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.